KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
11.64
-0.54 (-4.43%)
At close: May 13, 2025, 4:00 PM
11.50
-0.14 (-1.20%)
After-hours: May 13, 2025, 4:39 PM EDT
KalVista Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
150
Market Cap
578.69M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KALV News
- 11 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - Business Wire
- 4 weeks ago - KalVista: Poised For Rare Disease Transformation - Seeking Alpha
- 5 weeks ago - KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - Business Wire
- 2 months ago - KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire
- 2 months ago - KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - Business Wire